Version 1
: Received: 20 September 2023 / Approved: 20 September 2023 / Online: 21 September 2023 (03:32:12 CEST)
How to cite:
Brinza, M.; Uscatescu, V.; Himcinschi, M.; Chiriac, E.; Gherghe, G.; Coriu, D. Prophylactic Therapy with Emicizumab in Patients with Hemophilia A: Benefits and Challenges. Preprints2023, 2023091391. https://doi.org/10.20944/preprints202309.1391.v1
Brinza, M.; Uscatescu, V.; Himcinschi, M.; Chiriac, E.; Gherghe, G.; Coriu, D. Prophylactic Therapy with Emicizumab in Patients with Hemophilia A: Benefits and Challenges. Preprints 2023, 2023091391. https://doi.org/10.20944/preprints202309.1391.v1
Brinza, M.; Uscatescu, V.; Himcinschi, M.; Chiriac, E.; Gherghe, G.; Coriu, D. Prophylactic Therapy with Emicizumab in Patients with Hemophilia A: Benefits and Challenges. Preprints2023, 2023091391. https://doi.org/10.20944/preprints202309.1391.v1
APA Style
Brinza, M., Uscatescu, V., Himcinschi, M., Chiriac, E., Gherghe, G., & Coriu, D. (2023). Prophylactic Therapy with Emicizumab in Patients with Hemophilia A: Benefits and Challenges. Preprints. https://doi.org/10.20944/preprints202309.1391.v1
Chicago/Turabian Style
Brinza, M., Georgiana Gherghe and Daniel Coriu. 2023 "Prophylactic Therapy with Emicizumab in Patients with Hemophilia A: Benefits and Challenges" Preprints. https://doi.org/10.20944/preprints202309.1391.v1
Abstract
This study presents a transversal investigation, that we performed at Fundeni hospital, into the therapeutic benefits and efficacy of Emicizumab, a non-factor therapy, in the context of hemophilia A. Ten patients diagnosed with hemophilia A were closely monitored, using clinical and laboratory resources, during the course of Emicizumab treatment, with an average of 12.8 months. Among these patients, six exhibited anti-factor VIII inhibitors, changing the medical approach and adding complexity to their clinical profiles. A comprehensive approach was adopted to assess the coagulation status of patients under Emicizumab therapy. The study employed several key coagulation monitoring tools, of which including thrombin generation time (TGT) and thrombelastography (TEG). These methodologies proved highly valuable results in evaluating the patients' coagulation profiles during the treatment regimen. Additionally, traditionally coagulation assays were utilized to gain a comprehensive understanding of the overall coagulation dynamics. Noteworthy, impressive outcomes emerged from the study. During prophylaxis with Emicizumab all patients had experienced a reduced number of bleeding events. Moreover, a subset of these patients underwent major surgical procedures (orthopedic joint replacements) with successful outcomes. These findings underscore the potential of Emicizumab therapy as an effective option for hemophilia A patients, including those that presented a prompt production of anti-factor VIII inhibitors. As for the outcomes, this transversal study sheds some light on the positive impact of Emicizumab therapy in addressing the coagulation challenges posed by hemophilia A. The utilization of global coagulation assays, such as thrombin generation time, thrombelastography and combined with traditional coagulation assays, used as monitoring tools highlights their significance once more in evaluating the therapeutic response. This research contributes by providing physicians with valuable insights to the field, offering a potential avenue for improved patients’ care and treatment strategies that translate in enhanced quality of life for hemophilia A patients undergoing Emicizumab therapy.
Keywords
hemophilia A; inhibitors; Emicizumab
Subject
Medicine and Pharmacology, Hematology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
